Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1051-0443(91)72471-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Grating-based x-ray dark-field mammography: Assessing complementary imaging information in simple cystic lesions and typical fibroadenoma.
Med Phys
January 2025
Breast Imaging Department, Red Cross Hospital Munich, Munich, Germany.
Background: A significant proportion of false positive recalls of mammography-screened women is due to benign breast cysts and simple fibroadenomas. These lesions appear mammographically as smooth-shaped dense masses and require the recalling of women for a breast ultrasound to obtain complementary imaging information. They can be identified safely by ultrasound with no need for further assessment or treatment.
View Article and Find Full Text PDFFactors in Initial Anticoagulation Choice in Hospitalized Patients With Pulmonary Embolism.
JAMA Netw Open
January 2025
Department of Emergency Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield.
Importance: Despite guideline recommendations to use low-molecular-weight heparins (LMWHs) or direct oral anticoagulants in the treatment of most patients with acute pulmonary embolism (PE), US-based studies have found increasing use of unfractionated heparin (UFH) in hospitalized patients.
Objective: To identify barriers and facilitators of guideline-concordant anticoagulation in patients hospitalized with acute PE.
Design, Setting, And Participants: This qualitative study conducted semistructured interviews from February 1 to June 3, 2024, that were recorded, transcribed, and analyzed in an iterative process using reflexive thematic analysis.
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.
Cancer Immunol Immunother
January 2025
Liver Cancer Institute, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Introduction: This study aimed to evaluate the safety and preliminary efficacy of serplulimab, a novel programmed death-1 inhibitor, with or without bevacizumab biosimilar HLX04 as first-line treatment in patients with advanced hepatocellular carcinoma.
Methods: This open-label, multicenter phase 2 study (clinicaltrials.gov identifier NCT03973112) was conducted in China and consisted of four treatment groups: group A (serplulimab 3 mg/kg plus HLX04 5 mg/kg, subsequent-line), group B (serplulimab 3 mg/kg plus HLX04 10 mg/kg, subsequent-line), group C (serplulimab 3 mg/kg, subsequent-line) and group D (serplulimab 3 mg/kg plus HLX04 10 mg/kg, first-line).
Direct percutaneous puncture of occluded venous stents as an adjunctive technique to restore patency.
CVIR Endovasc
January 2025
Department of Radiology, Section of Vascular and Interventional Radiology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA, 98195, USA.
Thyroid Nodule Ablation: Ever Expanding Indications.
Radiol Imaging Cancer
January 2025
From the Division of Interventional Radiology, Beth Israel Deaconess Medical Center-Harvard Medical School, 1 Deaconess Rd, Rosenberg 3, Boston, MA 02215.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!